Stay updated on Daratumumab in PGNMID and C3 GN Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in PGNMID and C3 GN Clinical Trial page.

Latest updates to the Daratumumab in PGNMID and C3 GN Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedPage revision updated from v3.4.2 to v3.4.3. This appears to be a minor page update.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check32 days agoChange Detected- Updated page revision tag from v3.4.1 to v3.4.2; no impact on study content or user workflow.SummaryDifference0.1%

- Check40 days agoChange DetectedAn administrative version update is shown: 'Revision: v3.4.1' was added and 'Revision: v3.4.0' was removed. This appears to be metadata about the site and does not alter study data or page content.SummaryDifference0.1%

- Check54 days agoChange DetectedAdded UI elements and labels: Show glossary and Hide glossary, and updated metadata fields with 'Last Update Submitted that Met QC Criteria' and 'No FEAR Act Data', plus Revision: v3.4.0. Removed or replaced older labels: 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and Revision: v3.3.4.SummaryDifference0.4%

- Check61 days agoChange DetectedThe page now shows Revision: v3.3.4, replacing Revision: v3.3.3. No substantive content or layout changes are evident.SummaryDifference0.1%

- Check90 days agoChange DetectedAdded Minnesota as a location under the Locations section and removed the HHS Vulnerability Disclosure text/link from the footer.SummaryDifference0.2%

Stay in the know with updates to Daratumumab in PGNMID and C3 GN Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in PGNMID and C3 GN Clinical Trial page.